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Abstract
Purpose – The purpose of this paper is to explore patterns as well as determinants of regional
specialisation in China’s biopharmaceutical industry. It identifies and characterizes different types of
enterprises engaged in the biopharmaceutical sector in terms of their business organisation and
regional set up.
Design/methodology/approach – Based on data compilations not yet employed in academic
analysis as well as personal interviews in China, structural determinants and driving forces of
development are analysed against the background of the innovation systems literature.
Findings – The geography of innovation in China’s biopharmaceutical industry is determined by
both, government policy and the strategic location decisions of entrepreneurs. While local-government
support of firm clustering has contributed to a dispersion of industrial activity throughout China, the
firms” networks are spanning clusters. Effectively, domestic firms are turning into multi-regional
companies locating activities such as R&D and manufacturing at different clusters.
Originality/value – The paper adds to the literature in so far as it throws light on an until now
under-researched field of China’s innovation system. It identifies the concept of multi-regionalism
among domestic non-state enterprises as an important parameter for understanding success and
regional distribution of the industry.
Keywords China, Pharmaceuticals industry, Regional development, Government policy
Paper type Research paper
1. Introduction
Late-comer economies such as China have to master the art of catching-up growth in
order to copy and gradually emulate the development patterns of more advanced
economies. In a decade-long process they slowly, step-by-step reduce the development
gap and the technological distance separating them from their peers. However, Zeno’s
paradox seems to stand at the end of most of these development processes: Achilles
cannot outrun the tortoise and to late-coming economies it seems as if the leading
economies can never be surpassed, but always remain one step ahead. In order to
surpass this “final frontier”, late-comer economies have to depart from the catching-up
development model and establish autonomously created technological progress and
change as the primary source of their economic development. And only by venturing
into technological “terra incognita” and the establishment of technological leadership
in an area, where no other national science system and/or multinational corporation
has already staked its claims, can a late-developing economy really become
independent of its peers and eventually “outrun the tortoise”.
As the increasing returns associated with learning and experience provide first
movers in dynamic industries with a head start which is often enough sufficient to
leave subsequent competitors permanently behind, late-comer economies must focus
on new technological trajectories. Such new, unexplored scientific paths may open up
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“windows of opportunity” because at early stages of an emerging trajectory the
knowledge and capital required to compete successfully are still manageable (Perez and
Soete, 1988). The recent advances in nanotechnologies and biotechnology have been
widely viewed as providing such opportunities for the establishment of technological
leadership ahead of the established lead-economies (Niosi and Reid, 2007). Accordingly,
several developing countries, most notably China and India, have set out to seize their
chances. Since the late 1980s, the Chinese government has focused its efforts on
promoting the economy’s innovation capacity in a narrow set of high-technology fields.
One of these fields featuring prominently in the national development strategy is
biotechnology, a cross-cutting technology which can be employed, among others, in the
pharmaceutical, agricultural and energy industries. Among the potential users, China’s
central government, however, seems to target the pharmaceutical industry and
agriculture in particular (Yu, 2007).
The importance attributed to this field of research is also mirrored in the Medium to
Long-term program on Technological and Scientific Development (2006-2020).
This centrepiece of China’s modern innovation strategy contains several passages that
demonstrate the central government’s determination to catapult China’s health-related
biotechnology to the top of the global research activities (Cao et al., 2006). In particular,
biotechnology is listed first among the frontier technologies targeted, and two of the four
science mega projects enumerated in the “Program” – protein research and growth and
reproduction science – are directly related to health biotech.
Despite this strong government emphasis, English-language studies on China’s
biopharmaceutical industry are surprisingly limited. Most of them are emanating from
market research organizations such as BioPlan, Pharma China or Business Monitor
International, which supply information on general market developments and on key
players in the industry. Academic contributions predominately remain within the
field of biotechnological research per se and are intended to keep fellow researchers up
to date with the latest developments in China. Hence, this second set of studies
mainly focuses on the description of scientific results and breakthroughs in drug
development, while mentioning industrial dynamics only in passing (Hu et al., 2006).
Notably, Chen et al. (2007) and Yu (2007) go a step further by integrating their account
of biotechnology research into its regulatory and international context.
Scholars interested in economic development and innovation have so far remained
reticent or have discussed only very particular issues. Thomas (2009) and Salter (2009),
for example, deal with the problems of China’s pharmaceutical industry related to
IPR protection, respectively, the venture capital industry. Other authors have portrayed
outstanding Chinese research institutes in this field such as the Shanghai Institutes of
Biological Sciences (e.g. OECD, 2008). To our knowledge the first systematic analysis of
China’s biopharmaceutical industry has been provided by Frew et al. (2008)[1]. Their
discussion is based on an in-depth investigation of the product and patent portfolios,
financial backgrounds as well as collaborations and alliances of 22 Chinese
biopharmaceutical companies. Yet their knowledgeable account fails to embed the
firm-level analysis into the development and structure of the whole industry. Hence, it is
difficult to derive a more general picture of China’s biopharmaceutical industry.
In particular, China’s geography of innovation, which has been analyzed in scholarly
contributions on other Chinese industries (OECD, 2008; Segal, 2003; Sigurdson, 2005),
has been missed out. Prevezer and Tang (2006) examine the three biotechnology clusters
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in Beijing, Shanghai, and Shenzhen. Unfortunately, their selection of the clusters merely
rests on a number of enterprises, which they attained through searching incomplete and
possibly biased internet databases. Moreover, due to the omission of output indicators,
their discussion of the relative importance of regions and of enterprise types within these
regions may turn out to be highly deceptive.
Against this background, the present contribution seeks to supplement the
previous research by systematically examining the regional patterns and determinants
of specialization within this industrial sector. In order to do so, we make use of a unique
data source, the Annual Statistical Report on Pharmaceuticals in China (MIIT, 2009),
which offers a wealth of information on regional differences in industrial structure with
regard to the biopharmaceutical industry. To our knowledge, this report has not yet been
employed systematically in relevant research. In addition we base our discussion on the
comprehensive firm directory provided by BioPlan (2008), and explorative interviews
conducted in Shanghai and Beijing in February 2010.
The discussion opens with a theory-driven discussion of spatial patterns in sectoral
systems of innovation (SI) (Section 2). In particular, the role of government policy in the
geographical distribution of production and innovation will be emphasized. These
insights provide the basis for the subsequent analysis of China’s government policies
affecting the productivity and geography of China’s biopharmaceutical system. Before
China’s innovation policy is discussed in Section 4, an overview will be given on
China’s pharmaceutical industry with a particular focus on the biopharmaceutical
market segment (Section 3). As government policies merely provide a framework for
the strategic action of a broad range of actors, the location strategies of four types of
entrepreneurs and firms, which are important for the development of China’s
biopharmaceutical industry, will be analyzed in Section 5. Section 6 concludes.
2. Spatial dimensions of sectoral systems of innovation in China
In recent years, it has become widely accepted that in investigations of economic
development more holistic approaches have to be employed in order to catch a maximum
of relevant factors and processes (Lundvall, 2007). Among others[2], the SI approach
has been particularly influential as it has proven useful for analyzing the processes of
learning and innovation as the most important drivers of economic development.
Innovation is understood as a rule-based interactive process between several actors.
Accordingly, SI contain a set of organizations, e.g. firms, government (agencies) and
universities, and institutions, i.e. rules such as laws, social norms, and routines, which
give rise to certain forms and structures of interaction between (and within) these
organizations.
In general, two ways have been used to delimit the boundaries of SIs: geographical
and sectoral[3]. Sectoral systems focus on a specific knowledge base that is inherent to a
technological domain (Malerba, 2005). As knowledge and technologies change, the
product line-ups of a specific sector adapt consequently. In the pharmaceutical industry,
the biopharmaceutical segment was made possible due to new technologies such as
recombinant DNA technology and hybridoma technology, which facilitate the
production of recombinant proteins, respectively, monoclonal antibodies (mAbs).
The creation and diffusion of these new scientific knowledge bases and technological
opportunities is the outcome of interactions between firms and other actors including
universities, laboratories, and hospitals and the institutional framework that enable or
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disable knowledge exchange. In this sense, a spatial dimension is evident as formal
institutions (law and regulations) and policies are usually geographically confined. Most
of the SI literature focuses on this geographical dimension. Cooke et al. (1997) identify
three dimensions that are important for a given region’s innovative capacity: the
financial, learning, and “productive” cultural dimension. In principle, all of these
dimensions can be brought to play by spontaneous processes leading to a spatial
clustering of a complementary set of actors. But even if so, states play a significant role in
reinforcing or arresting development trajectories through their impact on either of the
three dimensions. The national system of innovation (NIS) perspective is based on the
acknowledgment of the state’s role in economic development (cp. Freeman, 1995).
The NIS approach predicts that industrial organization differs between countries and
that these differences account for the various countries’ differential ability to participate
and shape technological trajectories.
As such institutional approaches, sectoral and spatial SIs do not exclude each other but
are complementary. In fact, the sectoral perspective requires a spatial dimension but
leaves room for the interplay of institutional hierarchies. As Malerba (2005) claims, local,
national and global dimensions usually coexist in a given sector. The national level does
not necessarily have to dominate the other levels. In China, historical reasons have
rendered the sub-national level a decisive force in institutional change and industrial
growth. Two phases of political decentralization related to the Great Leap (1958-1960) and
the Cultural Revolution (1966-1976) have given local governments ample opportunities to
influence local development paths already in the pre-reform era. As a consequence, most
provinces had established a fledgling pharmaceutical sector during the early 1970s.
In 1976, there were about 2,600 mostly small-scale pharmaceutical plants scattered around
the country (CPEMA, 2009). The subsequent reform process initiated at the turn of the
1980s sanctioned and even broadened the devolution of authority (Qian, 2000). Effectively,
China evolved into a quasi-federal state with a complex division of labour and authority
between the central and the local governments. The fiscal reform of the 1980s has provided
local governments with additional sources of income that can be utilized in order to
advance the local economy. Accordingly, the function of local governments shows
prominently in government expenditure on science and technology (Figure 1).
The importance of both, national and local levels of the Chinese state would imply that
regional differences in pharmaceutical sector development are at least partly due to
Figure 1.
Government expenditure
for science and
technology, 1998-2008
Central gover local governm share of LG (ra)
1998 28.97 14.89 33.9%
1999 35.56 18.83 34.6%
2000 34.96 22.6 39.3%
2001 44.43 25.89 36.8%
2002 51.12 30.5 37.4%
2003 60.99 33.56 35.5%
2004 69.24 40.29 36.8%
2005 80.78 52.71 39.5%
2006 100.97 67.88 40.2%
2007 104.3 107.05 50.7%
2008 128.52 129.66 50.2%
Sources: NBS and MOST (2009); own illustration
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idiosyncratic local institutions and policies. Therefore, our expectation is, that an analysis
of sub-national dynamics can improve our understanding of how innovation works
in China. Sectoral studies with a local perspective have been already undertaken by,
e.g. Segal (2003) with respect to the computer industry and Thun (2006) regarding the
automobile sector. However, the focus on administrative boundaries has led both authors
to put a strong emphasis on government strategies, which easily gives an impression of
localities as being self-contained systems. Yet as will be shown in subsequent sections,
in recent years individual biopharmaceutical firms have been creating interrelationships
that span Chinese regions and even reach across the national border. We therefore add a
firm-level analysis based on a number of case studies in order to investigate how different
sets of firms have utilized local environments to create and adapt value creating network
structures. The main determinants of the spatial organisation of China’s industries, which
we have singled out for further investigation, are shown in Figure 2. In the following,
we first provide a short overview of China’s pharmaceutical industry. Then, we will turn to
each of these factors.
3. General overview of China’s pharmaceutical industry
During its first three decades of existence, the People’s Republic of China was quite
successful in substituting imports of most essential Western pharmaceuticals by
domestically manufactured drugs (Shen, 2008). Moreover, a number of medical schools
had been successfully instituted at leading universities. A number of research institutes,
particularly those of the prestigious Chinese Academy of Sciences (CAS), have
achieved major scientific breakthroughs (Yu, 2007; Ku¨hner, 1986). Such achievements,
however, remained scarce throughout the period. More importantly, the vertical central
planning system hampered the development of the sector as user-producer interactions
were notoriously absent. The established organizations were strongly specialized in
Figure 2.
Main determinants of the
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Source: Own illustration
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functions like R&D or manufacturing, while exchange between them was organized
by yet other bureaucratic organizations specialized in procurement and distribution
(Liu and White, 2001). This system was complicated by the concurrence of national and
local organizations that served these very functions. It was only when this centrally
planned division of labour was overcome in the 1980s through the permission of
decentralized market interaction – which also included direct science-industry
linkages – that industrial development really took off. Likewise, the commitment to
establish a market economy in the early 1990s was instrumental in exposing China’s
innovation system to foreign knowledge.
Growth in industrial output has been rapid throughout the last two decades. This also
applies to those five industrial sectors that are classified by the OECD as high-tech and
that are given the status of “pillar” industries by the Chinese central government.
Notably, growth has been uneven between these sectors. Although the pharmaceutical
industry enjoyed an eight-fold increase in output value between 1995 and 2008, it has
been clearly lagging behind the computer industry (Figure 3). Several reasons may
account for this difference in relative performance. Arguably, the most important of
them is that the computer industry has been strongly penetrated by foreign direct
investment (Figure 4). As has been discussed extensively in the literature, most of the
output growth of the latter industry is due to the large-scale relocation of Taiwanese
production networks to locations such as Dongguan in Guangdong province and
Figure 3.
Output growth in China’s
high-tech industries,
1995-2008 0% 100% 200% 300%
Sources: NBS et al. (2009); own illustration
400% 500% 600%
Medical equipment
and meters
Aircraft and
spacecraft
Electronic and
telecom
equipment
Computer and
office equipment
Pharmaceuticals
1995-2000
2000-2005
2005-2008
Medical equipment
and meters
Aircraft and
spacecraft
Electronic and
telecom equipment
Computer and
office equipment Pharmaceuticals
1995-2000 76.28% 44.10% 174.17% 373.10% 85.32%
2000-2005 205.61% 105.69% 181.99% 536.09% 138.61%
2005-2008 88.68% 50.41% 66.90% 54.62% 85.27%
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Kunshan in Jiangsu province[4]. In comparison, the pharmaceutical industry has
attracted substantially less FDI. Despite acceleration in recent years, the share of
foreign-invested enterprises (FIEs) in gross pharmaceutical output has increased only
from 19.6 percent in 1995 to 27.1 percent in 2008. Since 2005, however, the growth of both,
the computer and telecom sectors appear to slow down, while the pharmaceutical and
(even more so) the medical equipment sector have accelerated. Apparently, the leading
role in the growth of China’s pharmaceutical sector has been taken up by domestic
manufacturers and – in contrast to other industries – not foreign investors. All this
indicates different drivers and patterns of growth and development governing these
sectors.
Growth has been particularly strong in biological and biochemical
products. This segment includes genetically engineered drugs (recombinant
proteins), mAbs, vaccines, and also blood products. The biopharmaceutical industry
took off in the late 1980s, when China’s State Food and Drug Administration approved
the first indigenous genetically engineered drug, a recombinant alpha interferon
against hepatitis B and C. But although growth has been rapid since the late 1990s, the
segment is still small and accounted for merely 10.3 percent of China’s whole
pharmaceutical sector in 2008, up from 7.9 percent in 2005 (Figure 5). Much of this
growth is due to a rapid expansion in biogenerics, while novel (non-generic) products
have so far accounted for no more than an estimated single-digit percentage of sales.
The loss of patent protection for many products in recent years has rendered this
Figure 5.
China’s pharmaceutical
industry by output value
of market segment, 2008
Small molecul drugs                     49.6%
Biological & biochemical drugs   10.3%
Traditional chinese medicines       20.2%
Medical equipments                      10.5%
Others                                              9.3%
Source: Adapted from CPEMA (2009)
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FIEs’ share in high-tech
industrial output in
percent, 2008
Sources: NBS et al. (2009); own illustration
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choice a viable option to enter the industry. Technological barriers are rather low as
simple and mature expression systems are available to manufacture generics (Hu et al.,
2006). However, due to the low entry barriers, competition is also very strong for most
generic products.
Despite several efforts of the Chinese government to rationalize (i.e. promote
consolidation in order to create greater economies of scope and scale) the highly
fragmented economic structure, entry in the sector has been strong. In 2008, there were
more than 5,200 firms, 750 of which were doing biological and biochemical drugs
(CPEMA, 2009). Most of these enterprises were small-scale operations. Among the 750
firms in the bio segment, all but three were SMEs.
At the beginning of the reform era, the Chinese pharmaceutical industry was highly
fragmented and scattered around the country. This has basically remained a major
characteristic of China’s modern pharmaceutical industry as many provinces have
copied central policies and declared the national pillar industry “pharmaceuticals” as a
local “pillar” industry, as well. As a result, the Maoist feature of duplicated industry
structures allowing for a high degree of local autonomy but also foregoing the rents of
large-scale production and intensive interregional competition has been perpetuated in
the reform era. However, the various provinces are different in importance with regard
to gross industrial output, and their relative positioning has changed dramatically over
time. As it appears, firms in some provinces have expanded faster, or seen from a
different perspective, some provinces have managed to attract and nurture more
enterprises than others. Most notably, Shandong province has vastly increased its
share of gross pharmaceutical output to more than 14 percent of the national total
in 2008 (Figure 6). This surge in output appears to be concomitant to the acceleration of
biopharmaceutical development in the province. Indeed, Shandong’s share in total
national output is even larger in this segment (Table I). In turn, potential leaders in the
high-tech industries, in general, such as Beijing, Shanghai, and Guangdong have seen
their output shares decrease. Guangdong province, as it turns out today, is relatively
stronger in small molecules (i.e. chemical drugs) than in biopharmaceuticals.
4. China’s innovation policies and the biopharmaceutical industry
The Chinese state has supported the development of the biopharmaceutical industry
with a set of direct and indirect policy initiatives (Kroll et al., 2010). In principle,
China’s innovation policy can be divided into two phases: The first phase started with
the 1985 “Decision on the Reform of the S&T Management System”. On the one hand,
Figure 6.
Changes in the provincial
share of China’s gross
pharmaceutical output,
1995-2008
Sources: NBS et al. (2009); own illustration
1995 2000 2005 2008
Guangdong 10.40% 10.33% 6.75% 6.34%
Jiangsu 10.29% 8.93% 10.94% 11.08%
Zhejiang 5.93% 8.53% 9.95% 7.81%
Shanghai 8.21% 7.13% 5.11% 3.53%
Henan 5.61% 3.37% 4.33% 6.20%
Shandong 7.28% 5.67% 12.59% 14.22%
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major policy programs were launched, in particular the National High-Technology
R&D Program (“863 Program”) established in 1986. In conjunction with funds to
improve R&D facilities, the 863 program has been devised to provide funding for
research in a limited set of high-tech areas. On the other hand, the “Decision” put an
emphasis on forging links between the public research institutes and industrial
enterprises. By means of cutting government funding, public research institutes were
forced to sell their technologies and services to enterprises, i.e. to the state-owned
enterprises (SOEs), which dominated the economy at that time. Yet due to a lack of a
complementary institutional framework, “technology markets” did not get off the
ground but developed more than disappointingly.
The failure rested on the fact that most actors were still of the unwavering
conviction that scientific research and its innovations constituted a public good. As a
result enterprises often showed a habit of not paying royalties. At the same time,
however, SOEs were often neither willing, nor did they have the innovative capacity to
implement R&D projects. Given this constellation, public research institutes and
universities rather opted to commercialize their home-grown technologies themselves
(Eun et al., 2006). Central and local governments, in turn, responded to the emergence of
such academic spin-offs in a very accommodative manner and launched the Torch
Program, designed to provide a suitable infrastructure and institutional support for the
development of such technology-intensive enterprise start-ups.
The second phase started a decade later with the “Decision on accelerating the
progress in S&T”. At that time, the limits of the strong bias against basic research
which had resulted from the structural overemphasis on commercial usability of
innovation became evident. Although the Natural Science Foundation of China had
already been founded in 1986, basic research was rather neglected until the mid-1990s.
Only in 1997, the National Basic Research Program (“973 Program”) was launched in
order to strengthen basic research. Moreover, two programs, the 211 program and the
985 program, were initiated in 1995 and 1998, respectively, to give substantial
financial support to a small number of excellent research universities. The CAS
Knowledge Innovation Program introduced in 1998 was providing similar support for
the CAS.
Biopharmaceutical industry Pharmaceutical industry
Province
Gross output
(million RMB)
Share in total output
(%) Rank
Share in total output
(%) Rank
Shandong 17,589 20.2 1 14.2 1
Jilin 11,136 12.8 2 4.4 8
Jiangsu 8,119 9.3 3 11.1 2
Henan 7,826 9.0 4 6.2 5
Zhejiang 6,152 7.1 5 7.8 3
Guangdong 5,060 5.8 6 6.3 4
Shanghai 4,534 5.2 7 3.5 10
Beijing 3,965 4.6 8 3.4 13
Liaoning 3,862 4.4 9 3.4 11
Sichuan 2,725 3.1 10 5.4 6
Sources: MIIT (2009); NBS and MOST (2009)
Table I.
Provincial shares in gross
biopharmaceutical
output, 2008
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Among other high-tech sectors, these “big science” programs outlined above, i.e. the
863 and 973 programs, are targeting China’s biotech sector. As documented in Table II,
expenditures on both programs have prioritized health S&T. Interestingly, the funds
have been spent quite unequally among the different provinces. In 2006, the last year
when the regional distribution of 863 projects was published, Beijing accounted for more
than one-third while Shanghai attracted another eighth of all 863 projects (Figure 7).
This regional bias, however, does not come as a surprise as China’s major academic
R&D institutions are located in these metropolises. Although more recent numbers are
not published, it is therefore safe to conclude that the regional differences persist.
While enterprise R&D has been strongly increasing in recent years, most of the
more advanced research is done by academia, particularly by the institutes of the CAS
and major universities. This also applies for the 863 program: Almost 84 percent of the
projects are implemented by academia, whereas enterprises account for merely
15 percent. The same picture emerges on the output side. Patents are predominately
emanating from Shanghai and Beijing (Figure 8), which is due to their comparative
strength in academic research. Among the patent applicants, universities such as
Shanghai Fudan University, Shanghai Jiaotong University, and Tsinghua University
in Beijing as well as both cities’ CAS research institutes are particularly active in the
field of biotechnology. Patenting by domestic firms is on the rise in recent years, but
there are still no firms among the most prolific patentees (NDRC and CSBT, 2008).
Apparently, a new division of labour between academia and industry is currently
forged by the central government with academia intended to be mainly involved in basic
863 Program 973 Program
Field Share (%) Field Share (%)
Biotech & Pharmaceuticals 17.9 Human & Health Science 18.4
Information Technologies 13.7 Interdisciplinary Research 16.0
Energy Technologies 12.4 Materials Science 14.3
Materials Technologies 9.8 Environmental Science 14.1
Maritime Technologies 8.8 Agricultural Science 13.0
Note: Due to yearly fluctuations, a three-year average was calculated
Sources: MOST (2007); NBS and MOST (2009)
Table II.
Top 5
expenditure-categories
on key government
programs for S&T,
2006-2008
Figure 7.
Regional share of projects
of the 863 program, 2006
Beijing        35.50%
Shanghai        12.10%
Jiangsu          5.80%
Shandong          5.60%
Hubei          5.20%
Zhejiang          4.90%
Other provinc   30.90%
Shandong
5.6%
Other provinces
30.9%
Beijing
35.5%Shanghai
12.1%
Jiangsu
5.8%
Hubei
5.2%
Zhejiang
4.9%
Sources: MOST (2007); own illustration
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and applied basic research, while enterprises are supposed to take over the commercially
relevant R&D activities. As government is advocating an “enterprise-centred”
innovation system since the about turn of the century (Liu and Lundin, 2009),
government policies have gradually shifted from direct policies, i.e. the large-scale
programs, to indirect policies, i.e. institutional framework conditions trying to nudge
enterprise behaviour in specific directions by means of specific sets of incentives and
disincentives. This shift has been concurrent to a re-evaluation of the former focus on
large-scale “national champions” (Ernst and Naughton, 2008). In addition to establishing
the Innovation Fund for Technology-based SMEs in 1999, the constitution was amended
to increase the security of private property rights. The “big science” programs were
supplemented by tax incentives for R&D, government procurement policies for
innovative products and a move to better protect intellectual property rights. In October
2009, the third amendments to the patent law took effect. The amendments do not only
clarify issues concerning the patentability of designs, but also with respect to genetic
resources (Cheng, 2009), which is directly relevant for the biotechnology sector.
Efforts have also been undertaken to improve the framework for the venture capital
industry. In recent years, two new exit mechanisms have been introduced: In 2004, an SME
board was launched in Shenzhen and in October 2009, the ChiNext, a Nasdaq-style
growth board likewise located at the Shenzhen Stock Exchange, was opened. Initially,
28 companies are traded on the ChiNext, four of them pharmaceutical companies
(cf. Mitchell and Fu, 2010). Overall, China’s large banking sector and capital markets are
however not yet prepared to supply SMEs with finance. As an idiosyncrasy of the Chinese
system, local governments have stepped into provide start-up and growth capital
(White et al., 2005). The Torch Program mentioned above serves as a platform to extend all
sorts of preferential policies to targeted firms, with differences between localities.
Whereas the 863 and 973 programs are largely managed by the central government,
the Torch Program is handled by local governments that keep on intervening directly to
support economic and corporate development in their localities. The Torch Program is set
up as an infrastructure program supporting technology-intensive firms through
the establishment of industrial zones and incubating facilities. The centrepiece of the
program are the “high and new technology industry development parks”. Until recently,
56 of them have been sanctioned by the central government as national-level parks, while
about 120 local-level parks exist. Within these parks, some specialized incubating
facilities have been established. Among them, 62 national-level university parks are
Figure 8.
Domestic applications for
invention patents in the
field of biotechnology,
1997-2006
Shanghai 4,061
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Jiangsu 1,140
Guangdong 1,069
Zhejiang 795
Hubei 692
Shandong 684
Tianjin 461
Liaoning 413
Sichuan 376
Source: Adapted from NDRC and CSBT (2008)
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catering to academic spin-offs. Some other parks have targeted returnees, i.e. Chinese
professionals with academic and work experience abroad, which are willing to establish
an enterprise in China. Moreover, specialized industrial bases have been set up under the
Torch Program, which are supposed to support industrial clustering. Almost 30 of these
bases are targeting the pharmaceutical industry, most of which are located in Jiangsu
province and Shandong province (Table III).
5. Strategic location decision and regional specialization
The Chinese state’s innovation policies constitute an important part in the environment
governing the development of the biopharmaceutical industry. Arguably, these
policies have made a reasonably strong contribution to strengthening domestic health
biotech R&D and to commercializing research results. Government policy has also
sought to influence the spatial structure of China’s biopharmaceutical industry. In fact,
one of the key ideas behind the Torch Program was and still is the stimulation of
cluster synergies and the realization of positive network externalities. The devolution
of regulatory authority over the local economy and command over sizable budgets
have provided local governments with the means to foster industries within their
jurisdictions. Given this constellation and the fact that government intervention into
industry development is particularly strong in China, research on regional innovation
systems has usually concentrated on local government policies and initiatives
(e.g. OECD, 2008). However, firm clusters are not only the outcome of purposeful
government action but are also determined by a broad range of other determinants
Number
of tenants
Industrial
output value
(million RMB)
Exports
(million USD)
Jiangsu Province
China Torch Program “Three Medicine” Industrial Base
of Changzhou City’s Xinbei District 89 9,400 248
China Torch Program Advanced Medicine Industrial
Base of Lianyungang 24 7,682 26
China Torch Program Biological Medicine Industrial
Base of Qidong (Nantong) 21 4,286 31
China Torch Program Medicine Industrial Base of
Taizhou (Jiangsu) 202 19,530 660
China Torch Program Wuzhong Medicine Industrial
Base (Suzhou) 20 5,307 158
China Torch Program Pukou Biological Medicine
Industrial Base of Nanjing 21 1,502 0.5
Shandong Province
China Torch Program Biology Engineering and
Advanced Medicine Industrial Base of Jinan 80 2,988 21
China Torch Program Biology Industrial Base of Jining 35 9,289 47
China Torch Program Biology Industrial Base of
Yucheng (Dezhou) 25 2,735 20
China Torch Program Biological Medicine Industrial
Base of Zibo 42 12,302 298
Source: Torch (2009)
Table III.
Torch Program drug
manufacturing parks at
Jiangsu and Shandong
in 2008
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and decisions made by decentral actors that are involved in enterprise
formation. The strategic location decision these actors make are a decisive factor for
understanding the spatial dimension of production and innovation in China. Thus, we
now turn to the micro level of China’s industry evolution in order to better appreciate
the determinants of the spatial distribution of biopharmaceutical companies over
the country. We distinguish between four types of firms: state-owned business groups,
FIEs, returnee enterprises and domestic non-state enterprises.
State-owned business groups
When reforms started in the early 1980s, China had already established a basic
structure of pharmaceutical plants and pharmaceutical research institutes. The location
of plants and institutes resulted from the decisions of the central planning authorities
guided by temporally varying political (and military) considerations. For example,
the launch of the “third front” in the mid-1960s aiming at establishing a complete
industrial base in China’s hinterland contributed to a geographical dispersion of
the initial sectoral system. During the 1980s, the central government started to
encourage the formation of business groups with the objective of emulating Japan’s
and Korea’s development model (Keister, 2009). Existing enterprises were connected
under a state holding structure but this was not accompanied by a relocation of plants.
In many cases, this group structure was existing on paper only, but in other cases
relatively frequent in-group trade and financial interactions emerged. A notable
problem, due to the strong specialization of the pre-reform era, the plants had a very
limited innovative capacity, which hampered the reform of SOEs. One way to solve the
problem was seen in merging public R&D institutes with SOEs, but this approach
largely failed (Gu, 1999).
As the biopharmaceutical sector emerged rather recently, the state-owned groups
populating this segment have not had the problems the traditional SOEs faced. The most
important group, the China National Biotec Group (CNBG),[5] is one of a new-style type
of SOEs that has emerged particularly since the late 1990s. When many
industry-specific ministries were abolished in 1998, the research institutes formerly
subordinated to these ministries were to a large extent transformed into enterprises.
In 1999, the first badge of 242 research institutes started this peculiar transformation
process followed by institutes of other ministries and local governments (Sigurdson,
2005). The CNBG anticipated these transformations. Its predecessor, the China National
Biological Product Corporation was formed in 1989 following the corporatization of
seven research institutes subordinate to the Ministry of Health. These institutes for
biological products are spread all over the country, being located in Changchun (Jilin
province), Chengdu (Sichuan province), Lanzhou (Gansu province), Shanghai, Beijing,
and Wuhan (Hubei province). In addition, two biopharmaceutical manufacturers have
been integrated into the group at a later stage: Beijing Tiantan Biological Products,
established in 1998 by the Beijing Institute of Biological Products, and Chengdu
Rongsheng Pharmceuticals, established in 1997 by the Chengdu Institute of Biological
Products (BioPlan, 2008). CNBG, headquartered in Beijing, is the leading manufacturer
of vaccines and blood products.
Due to the dispersion of institutes-turned-companies, some provinces have been put
on the map of China’s biopharmaceutical industry, although they feature no start-up
community or cluster initiatives. An example in case is the Lanzhou Institute of
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Biological Products, which accounts for more than 90 percent of Gansu’s sales revenues
in this market segment.
Foreign-invested enterprises
One of the key features of China’s high-tech industries is the high share of FIEs in
domestic market and export sales revenue. But, although FIEs are also playing a role in
the pharmaceutical industry, industry penetration by FIEs was until recently not nearly
as high as, for example, in the computer industry (Figure 4). This also applies for the
biopharmaceutical segment, even though the share of FIEs is more than ten percentage
points higher than for the whole industry (Figure 9). Unsurprisingly, FIEs have not
spread evenly across the country. The majority of gross output in Jilin, Tianjin, and
Shanghai is produced by FIEs. In Shandong and Jiangsu the share is lower but this is due
to the strong performance of domestic manufacturers. In absolute terms, the output of
FIEs in Shandong is higher than that of the FIEs in the three provinces listed above
combined.
During the 1980s and 1990s, China has attracted FDI on a large-scale by establishing
an export-processing regime (Naughton, 2007). In particular, the strong performance of
China’s computer industry has been due to the integration into Asian production
networks. This integration was made possible by the relocation of component suppliers
from Greater China, most importantly Taiwan, to the mainland. As a consequence,
foreign trade surged with FIEs being responsible for almost all exports (Gaulier
et al., 2007). In the biopharmaceutical industry, however, different development patterns
apply. Exports have not been the main driver of the biopharmaceutical industry. In 2008,
exports accounted for just 10 percent of total sales revenue. They were also not the main
reason for FDI in this industry as merely 16 percent of FIEs’ sales are due to foreign
trade. Altogether, FDI into this industry has been lagging behind that in other high-tech
industries, and foreign investors appear to mainly target the post-WTO domestic
market. But there are some notable geographical differences. In those provinces, where
FDI is particularly strong such as Jilin, Tianjin, Shandong, and Shanghai, FIEs
are dominating exports (Figure 10). In Jiangsu and especially in Zhejiang the absolute
value of FIE exports is high, but the main exporters are domestic companies. Most
surprisingly, the exporting powerhouse, Guangdong province, contributes rather
weakly to China’s pharmaceutical exports. And most of these exports are done by
Figure 9.
FIEs’ share of provincial
biopharmaceutical
output, 2008
Sources: MIIT (2009); own illustration
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domestic manufacturers. Since the province’s FIEs contribute more than 40 percent of
provincial pharmaceutical output value, these companies are obviously focusing on the
domestic market and not on exports.
Besides manufacturing, FIEs may also be attracted to conduct other activities in
China. Indeed, in recent years many multinational companies have set up R&D
establishments in China. Xue and Liang (2008) show on the basis of the Business Week
1000 that most of the autonomous R&D centres are located in Beijing and Shanghai,
while foreign corporate R&D centres in other provinces are usually attached to
manufacturing activities. In the pharmaceutical industry, Shanghai was particularly
successful in attracting foreign R&D centres. While multinationals such as
Novo Nordisk have established an R&D centre in Beijing, most of the newly
established autonomous institutes, including those of Astra Zeneca, Glaxo Smith Kline,
and Eli Lilly are situated in Shanghai’s Zhangjiang science park. The operations of the
multinationals are clearly regionally specialized. Novo Nordisk has its R&D centre in
Beijing and its manufacturing base in neighbouring Tianjin; Eli Lilly opened its R&D
centre in Shanghai, while keeping its manufacturing operations in Suzhou (Jiangsu
province). Notably, Shanghai differs to most other cities, including Beijing, in that the
city has attracted both, foreign R&D and manufacturing.
But on the whole, the division of labour is that Shanghai, and to some extent
Beijing, is attracting research-intensive foreign activities, while other provinces act as
manufacturing bases. This has several advantages: In Beijing and Shanghai are the
major research institutes and universities that provide both, high-skilled labour
and access to domestic R&D output. Eli Lilly, for example, works closely with domestic
contracted research organizations in Shanghai ( Jia, 2009). In turn, most of the
manufacturing takes place in the direct surrounding of Beijing, i.e. Tianjin, and of
Shanghai, i.e. the cities in Jiangsu bordering Shanghai, where land and labour is less
expensive.
Figure 10.
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Returnee enterprises
In recent years, the phenomenon of return migration has gained increased attention.
Significant numbers of Chinese (and Indian) entrepreneurs with extended study and
work experience in developed countries, in particular the USA, have returned to their
home countries to improve the research landscape or start an own company. These
highly skilled individuals keep contact to their former host country and effectively
span networks (Saxenian, 2005). China’s biopharmaceutical industry has vastly gained
from this return migration and local governments have been competing to provide the
best incentive packages designed to lure these companies to locate in their parks.
Examples of returnee enterprises abound, including WuXi AppTech (formerly Wuxi
PharmaTech) located in a city of Jiangsu province near Shanghai, which is an outsourcing
firm that assumes laboratory and manufacturing services for leading pharmaceutical
companies such as Merck. Shandong Simcere Medgenn Bio-pharmaceutical, which was
founded by a returnee with a PhD degree from the Department of Molecular and Cell
Biology at the University of California at Berkeley, has pioneered a recombinant protein
against non-small-cell lung cancer. ACON Laboratories, a diagnostic company founded by
a returnee from the US, is one of China’s top pharmaceutical companies with respect to
revenues. As it is focusing on the international markets, it is one of the companies that
explain the excelling export performance of Zhejiang province.
As it appears, returnee enterprises are usually not established in Beijing and
Shanghai but rather in provinces such as Jiangsu, Zhejiang, and Shandong. Despite
their relatively strong R&D performance, they rather locate in areas that are also
targeted by foreign multinationals as manufacturing bases. This may be due to the fact
that many returnee enterprises are more focused on international relationships
(Frew et al., 2008). This approach is different to that of leading multinationals, which
decide to locate their more R&D-intensive operations in the major municipalities in
order to tap the local knowledge base.
Domestic non-state enterprises
The types of firms covered so far have powerful relationships to potent actors and
access to financial resources. As has been pointed out, China’s banking sector is
strongly geared towards financing SOEs (Lardy, 1998; Huang, 2003). At the same time,
Chinese subsidiaries of multinational firms have sufficient financial support from their
parent company to expand into the Chinese market. In turn, some of the more
successful returnee firms have international ties that help in accessing sources of
capital. Foreign venture capitalists have especially targeted these returnee enterprises.
Recently, they have also been targeted by local governments that want to expand the
economy within their jurisdiction.
Domestic non-state SME, private or not, in comparison have much less access to
financial resources. In order to compensate for this disadvantage, however, many of
these companies have started to shop around the country in order to access local
governmental sources of capital. As a result the picture of a large numbers of small-scale
enterprises scattered around the country, which suggests a highly fragmented
structure, is misleading. In reality many of these enterprises are, in fact, interrelated and
constitute multi-regional enterprises striving to tap as many local sources of finance as
possible. A representative firm is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical.
The company was established in 1996 by six teachers from Fudan University.
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In the development of the firm, the Shanghai government was instrumental. In fact,
Zhangjiang High-tech Park, which is managed by the municipal government, is one of
the major shareholders of the joint-stock company. Following a strategy similar to the
one of multinationals like Eli Lilly, the company has established a manufacturing firm in
Taizhou (Jiangsu province). In lieu for this location decision, the Taizhou government
has invested strongly into Fudan-Zhangjiang’s manufacturing firm. Other companies
have followed similar strategies. In fact, in our interviews, most respondents have stated
that local governments have been quite generous in supporting the development of their
firms or their subsidiaries. Hence, one of the major reasons why some provinces have
increased their share of total pharmaceutical output value appears to be that they have
provided the best conditions for this type of firms, in particular with regard to finance.
The parks, which have been established by local governments, have by some authors
been viewed as a waste of resources, because a technology-intensive industry like the
biopharmaceutical industry needs adequate R&D, which is not given in many localities
outside Beijing and Shanghai (Jia et al., 2003). While this cannot be denied in some
instances, critics have failed to see the increasingly complex and value creating relations
between enterprises from different regions. While a decade ago, firms usually remained
within the confines of their locality, the recent improvement of property rights delineation
and protection has rendered multi-regional enterprise groups a viable option. In their
expansion, small local firms have turned into highly capacitated multi-regional
enterprises – for reasons that differ from those of their foreign counterparts. As banks are
still inefficient in their fund allocation and domestic stock markets immature, the financial
support extended by local governments via park administrations and government venture
capital funds has been extremely useful in the expansion of an indigenous industry.
6. Conclusion
In recent years, a number of biopharmaceutical companies with high potential have
emerged in China. These companies have proven their ability to innovate sophisticated
drugs based on biotechnology. Indeed, the first enterprise worldwide that put a gene
therapy drug on the market, was SiBiono Genetech, a Chinese company. Yet although
China appears to catch up in this market segment, our knowledge of this industry
remains very limited. We understand this contribution as an exploratory exercise
designed to shed some additional light on the structural build-up and especially the
specific regional parameters shaping China’s biopharmaceutical industry.
Based on the information compiled, we have outlined China’s geography of
innovation. As a result of both, government policy and the strategic location decision
of economic actors, several firm agglomerations have developed in China. As it appears,
a regional division of labour is gradually emerging. Beijing and, even more importantly,
Shanghai is turning into an internationalized hub for advanced R&D, while the
provinces surrounding these municipalities have attracted manufacturing activities of
both, foreign and domestic enterprises. This division of labour is driven in particular by
the financing needs of enterprises. As China’s capital markets are still rather immature,
local governments have taken over an important role as venture capitalists. As these
governments cannot provide a substitute for private venture funding, the development
of the industry will be hampered as long as China does not manage to establish a proper
capital market. Moreover, as governments have biased incentives, venture financing
may lead to a geographical dispersion of the industry that is not viable in the long run.
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The problem of geographical dispersion may, however, be not as problematic as is
often portrayed in the literature. Many of the impulses for enterprise formation and
expansion in China actually originate from Shanghai or Beijing. It is the firms and
research organizations of these cities, which are responsible for a large number of
enterprise start-ups not only in these two cities, but all over China. Therefore, it does
not suffice to look at the institutional and infrastructural environment of an individual
cluster in order to evaluate a firm’s support for innovative activities. In China, there
appears to exist two diametrical tendencies: On the one hand, we can see firm
clustering in a number of localities. But on the other hand, these firms’ networks are
interregional. The interactions across clusters constitute a highly interesting
development that requires further research.
In any case, it seems as if the Chinese Achilles is learning how to solve Zeno’s
paradox and outrun the tortoise – not yet, but probably soon.
Notes
1. There has been an earlier analysis provided by Liu and Lundin (2007). But their paper has
remained at a preliminary stage.
2. Other approaches include Whitley’s (1999) “national business systems”, Amable’s (2003)
“social SI and production”, and Porter’s (1990) “industrial clusters”.
3. A third way to identify boundaries would be in terms of particular technologies (Carlsson
et al., 2002). However, this approach appears rather challenging, because most technologies
are used in different industrial sectors featuring quite distinctive organizational processes.
4. See Gaulier et al. (2007) and Yang (2009). Indigenous enterprises made an appearance in the
international markets as well, including Legend/Lenovo in the computer industry, and
Huawei in the telecom equipment sector. Zhou (2008) and Ernst and Naughton (2008) have
argued convincingly that these enterprises profited from the influx of FDI.
5. In September 2009, the State Assets Supervision and Administrative Commission, which
exercises the property rights of the state, announced that CNBG will be merged with China
National Pharmaceutical Group (Sinopharm), an old-style SOE (Business Forum China 6/09).
Whatever the reasons, CNBG will cease to exist, but this will not decisively change the
organization of the subordinate enterprises.
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